North America Neutropenia Treatment Market By Distribution channel (Retail pharmacies, Hospital pharmacies and Online pharmacies), By Treatment (Colony-stimulating factor, Antibiotics, Antifungals and Antivirals), By Country, Industry Analysis and Forecast, 2020 - 2026
The North America Neutropenia Treatment Market would witness market growth of 5.5% CAGR during the forecast period (2020-2026).
Neutropenia can compromise optimal cancer treatment by increasing, delaying, or even discontinuing the dose of chemotherapy. Such dose modifications are often made during the initial stages of chemotherapy, as neutropenic symptoms frequently occur early in the process of chemotherapy. Treatment response often depends on the delivery of standard chemotherapy doses, and changes in dosing may threaten complete response rates and reduce survival. Caregivers, therefore, face the challenge of maintaining adequate chemotherapy doses while managing neutropenic complications. The evaluation of chemotherapy-induced neutropenia is gaining significance.
Children often experience fever with severe neutropenia. They are given antibiotics to combat infection as they do, so they will need to be Retailized. Repeated use of antibiotics can, however, have side effects such as the production of drug-resistant bacteria, diarrhea or enterocolitis, and inflammation of the intestines. Some antibiotics may have adverse effects on the function of the kidney and liver.
New medications have been designed to support the bone marrow to produce neutrophils and improve the body's protection against infection. These drugs are referred to as granulocyte colony-stimulating factors. They help keep neutrophils in the blood above the level of danger all or most of the time. The shorter the time the neutrophil count is low, the less likely your child will develop a fever or infection. These drugs can reduce the amount and seriousness of infections and reduce Retailizations.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
Neutropenia can compromise optimal cancer treatment by increasing, delaying, or even discontinuing the dose of chemotherapy. Such dose modifications are often made during the initial stages of chemotherapy, as neutropenic symptoms frequently occur early in the process of chemotherapy. Treatment response often depends on the delivery of standard chemotherapy doses, and changes in dosing may threaten complete response rates and reduce survival. Caregivers, therefore, face the challenge of maintaining adequate chemotherapy doses while managing neutropenic complications. The evaluation of chemotherapy-induced neutropenia is gaining significance.
Children often experience fever with severe neutropenia. They are given antibiotics to combat infection as they do, so they will need to be Retailized. Repeated use of antibiotics can, however, have side effects such as the production of drug-resistant bacteria, diarrhea or enterocolitis, and inflammation of the intestines. Some antibiotics may have adverse effects on the function of the kidney and liver.
New medications have been designed to support the bone marrow to produce neutrophils and improve the body's protection against infection. These drugs are referred to as granulocyte colony-stimulating factors. They help keep neutrophils in the blood above the level of danger all or most of the time. The shorter the time the neutrophil count is low, the less likely your child will develop a fever or infection. These drugs can reduce the amount and seriousness of infections and reduce Retailizations.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies and
- Online pharmacies
- Colony-stimulating factor
- Antibiotics
- Antifungals and
- Antivirals
- US
- Canada
- Mexico
- Rest of North America
- Amgen, Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- BeyondSpring, Inc.
- Spectrum Pharmaceuticals, Inc.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Mylan N.V.
- Cellerant Therapeutics, Inc.
- Partner Therapeutics, Inc.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Neutropenia Treatment Market, by Distribution Channel
1.4.2 North America Neutropenia Treatment Market, by Treatment
1.4.3 North America Neutropenia Treatment Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL
3.1 North America Retail pharmacies Market by Country
3.2 North America Hospital pharmacies Market by Country
3.3 North America Online pharmacies Market by Country
CHAPTER 4. NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY TREATMENT
4.1 North America Colony-stimulating factor Market by Country
4.2 North America Antibiotics Market by Country
4.3 North America Antifungals Market by Country
4.4 North America Antivirals Market by Country
CHAPTER 5. NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY COUNTRY
5.1 US Neutropenia Treatment Market
5.1.1 US Neutropenia Treatment Market by Distribution channel
5.1.2 US Neutropenia Treatment Market by Treatment
5.2 Canada Neutropenia Treatment Market
5.2.1 Canada Neutropenia Treatment Market by Distribution channel
5.2.2 Canada Neutropenia Treatment Market by Treatment
5.3 Mexico Neutropenia Treatment Market
5.3.1 Mexico Neutropenia Treatment Market by Distribution channel
5.3.2 Mexico Neutropenia Treatment Market by Treatment
5.4 Rest of North America Neutropenia Treatment Market
5.4.1 Rest of North America Neutropenia Treatment Market by Distribution channel
5.4.2 Rest of North America Neutropenia Treatment Market by Treatment
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.1 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Neutropenia Treatment Market, by Distribution Channel
1.4.2 North America Neutropenia Treatment Market, by Treatment
1.4.3 North America Neutropenia Treatment Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL
3.1 North America Retail pharmacies Market by Country
3.2 North America Hospital pharmacies Market by Country
3.3 North America Online pharmacies Market by Country
CHAPTER 4. NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY TREATMENT
4.1 North America Colony-stimulating factor Market by Country
4.2 North America Antibiotics Market by Country
4.3 North America Antifungals Market by Country
4.4 North America Antivirals Market by Country
CHAPTER 5. NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY COUNTRY
5.1 US Neutropenia Treatment Market
5.1.1 US Neutropenia Treatment Market by Distribution channel
5.1.2 US Neutropenia Treatment Market by Treatment
5.2 Canada Neutropenia Treatment Market
5.2.1 Canada Neutropenia Treatment Market by Distribution channel
5.2.2 Canada Neutropenia Treatment Market by Treatment
5.3 Mexico Neutropenia Treatment Market
5.3.1 Mexico Neutropenia Treatment Market by Distribution channel
5.3.2 Mexico Neutropenia Treatment Market by Treatment
5.4 Rest of North America Neutropenia Treatment Market
5.4.1 Rest of North America Neutropenia Treatment Market by Distribution channel
5.4.2 Rest of North America Neutropenia Treatment Market by Treatment
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.1 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:
LIST OF TABLES
TABLE 1 NORTH AMERICA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 2 NORTH AMERICA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 3 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 4 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 5 NORTH AMERICA RETAIL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 NORTH AMERICA RETAIL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 NORTH AMERICA HOSPITAL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 NORTH AMERICA HOSPITAL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 NORTH AMERICA ONLINE PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 NORTH AMERICA ONLINE PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 12 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 13 NORTH AMERICA COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 NORTH AMERICA COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 NORTH AMERICA ANTIBIOTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 NORTH AMERICA ANTIBIOTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 NORTH AMERICA ANTIFUNGALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 NORTH AMERICA ANTIFUNGALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 NORTH AMERICA ANTIVIRALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 NORTH AMERICA ANTIVIRALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 US NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 24 US NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 25 US NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 26 US NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 27 US NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 28 US NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 29 CANADA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 30 CANADA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 31 CANADA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 32 CANADA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 33 CANADA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 34 CANADA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 35 MEXICO NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 36 MEXICO NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 37 MEXICO NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 38 MEXICO NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 39 MEXICO NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 40 MEXICO NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 41 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 42 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 43 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 44 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 45 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 46 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 47 KEY INFORMATION – AMGEN, INC.
TABLE 48 KEY INFORMATION – NOVARTIS AG
TABLE 49 KEY INFORMATION – PFIZER, INC.
TABLE 50 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 51 KEY INFORMATION – BEYONDSPRING, INC.
TABLE 52 KEY INFORMATION – SPECTRUM PHARMACEUTICALS, INC.
TABLE 53 KEY INFORMATION – KYOWA KIRIN CO., LTD.
TABLE 54 KEY INFORMATION – MYLAN N.V.
TABLE 55 KEY INFORMATION – CELLERANT THERAPEUTICS, INC.
TABLE 56 KEY INFORMATION – PARTNER THERAPEUTICS, INC.
TABLE 1 NORTH AMERICA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 2 NORTH AMERICA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 3 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 4 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 5 NORTH AMERICA RETAIL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 NORTH AMERICA RETAIL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 NORTH AMERICA HOSPITAL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 NORTH AMERICA HOSPITAL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 NORTH AMERICA ONLINE PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 NORTH AMERICA ONLINE PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 12 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 13 NORTH AMERICA COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 NORTH AMERICA COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 NORTH AMERICA ANTIBIOTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 NORTH AMERICA ANTIBIOTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 NORTH AMERICA ANTIFUNGALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 NORTH AMERICA ANTIFUNGALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 NORTH AMERICA ANTIVIRALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 NORTH AMERICA ANTIVIRALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 US NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 24 US NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 25 US NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 26 US NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 27 US NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 28 US NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 29 CANADA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 30 CANADA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 31 CANADA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 32 CANADA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 33 CANADA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 34 CANADA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 35 MEXICO NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 36 MEXICO NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 37 MEXICO NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 38 MEXICO NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 39 MEXICO NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 40 MEXICO NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 41 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 42 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 43 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 44 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 45 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 46 REST OF NORTH AMERICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 47 KEY INFORMATION – AMGEN, INC.
TABLE 48 KEY INFORMATION – NOVARTIS AG
TABLE 49 KEY INFORMATION – PFIZER, INC.
TABLE 50 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 51 KEY INFORMATION – BEYONDSPRING, INC.
TABLE 52 KEY INFORMATION – SPECTRUM PHARMACEUTICALS, INC.
TABLE 53 KEY INFORMATION – KYOWA KIRIN CO., LTD.
TABLE 54 KEY INFORMATION – MYLAN N.V.
TABLE 55 KEY INFORMATION – CELLERANT THERAPEUTICS, INC.
TABLE 56 KEY INFORMATION – PARTNER THERAPEUTICS, INC.
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
